Agen's cardiovascular test sales stable
This article was originally published in Clinica
Australian manufacturer of human and veterinary rapid tests, Agen, has reported a 12% decline in sales to Aus$8.4 million ($6.4 million) in fiscal 1995 (ended June). Cardiovascular product sales remained steady at about Aus$4 million the company says. Its operating loss after one-off charges fell to Aus$404,000 compared with Aus$3.3 million in the previous year.